Home

The Research Group of Immunology and Rheumatology

The Dendritic Cell Group

The overall aim of our research is to further unravel the mechanisms by which dendritic cells modulate T cell responses, both in autoimmunity as well as tumor immunity. Our results will lead to a better understanding of the cellular mechanisms involved in antigen presentation, T cell stimulation and tolerance induction, thereby revealing new tools for diagnosis and targets for therapy of patients with cancer, autoimmune and infectious diseases as well as patients undergoing stem cell transplantation. Thus, it will lead to an increased survival and better quality of life for patients.

group_picture

Projects and current members within the group

 

Silje Michelsen Solberg, MD, PhD fellow

Monitoring and improving treatment of psoriasis

A major challenge in the clinic is predicting which patients will need biopharmaceuticals and what the efficacy of different drug regimes will be on individual psoriasis patients. Currently, patients are first evaluated for the efficacy of standard, non-biopharmaceutical treatments before proceeding to empirical testing with different biopharmaceuticals. Insights that can provide predictive markers of which patients that will require biopharmaceuticals and which biopharmaceutical that will have efficacy in different psoriasis patients would be of great value. In this project, we will use phospho-flow and mass cytometry for single-cell-network profiling for patient stratification.

Anders Krogh Aarebrot, Medical student research program (“forskerlinjestudent”)

Monitoring and improving treatment of psoriasis

In this project we want to combine phosphoflow as well as clinical and biological investigations with the overall aim of gaining insights to psoriasis treatment and deepening understanding of disease pathophysiology.

Aleksandra Petrovic, MD, PhD fellow

Towards personalized therapy – the effect of biopharmaceutical treatment on peripheral immune cells in psoriasis

Psoriasis is a chronic, inflammatory disease of the skin with increased risk of comorbidities. Patients with severe disease require treatment with cost-intensive biopharmaceuticals. It is still unknown which patient will respond adequately to a certain drug. Therefore, there is the need for better patient stratification to responders and non-responders to a given treatment. Quantification and assessment of various immune cell populations, especially dendritic cells, in peripheral blood of psoriasis patients prior to and after treatment will give us information regarding initiation and maintenance of the inflammatory pathways in psoriasis.

Irene Sarkar, PhD fellow

Towards new biomarkers for stratification of patients with primary Sjögren’s syndrome

The overall goal is to stratify patients with primary Sjögren's syndrome based on single-cell-network-profiling using mass cytometry in order to improve diagnostics and treatment modalities for this heterogeneous patient group. This will give insight into the underlying pathologic mechanisms.

Dag Heiro Yi, MD, PhD fellow

Immunotherapy using dendritic cells (DC) has been shown to be safe, but the clinical results so far have been rather disappointing. Dag’s project focuses on improving the quality of dendritic cells (DCs) used in immunotherapy.